At GW Pharmaceuticals, we remain committed to ensuring our patients, healthcare partners and employees are supported during these challenging times. We are actively monitoring our supply chain and taking steps to help ensure continued supply of our products to patients. We will continue to monitor the COVID-19 situation and take steps to ensure that access and assistance for patients and healthcare partners remain consistent. If you wish to discuss more specific details please contact GW Pharmaceuticals via phone on +44 (0) 1223 238170 or via email at

If you are reporting an Adverse Event and / or a Product Complaint, and you receive a network busy signal (i.e. if all lines are busy or engaged) please continue to try your call throughout the day or, preferably report via the above email address.

Scott Giacobello

Chief Financial Officer

“We don’t simply say we put patients first, we live it. That’s what fuels me.”

Scott Giacobello is GW’s chief financial officer, a role he has held since joining the company in March 2017. He has more than 25 years of finance and operational experience.

As CFO, Scott is responsible for the company’s finance, accounting, tax, treasury, corporate strategy and business development activities.

Prior to GW, Scott served as chief financial officer for Chase Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialisation of improved treatments for neurodegenerative disorders, until its acquisition by Allergan in late 2016. From 2008-2015, he held senior level finance positions at Allergan, including vice president of finance for global research and development, vice president of corporate finance and vice president of internal audit and compliance. He also held finance roles at Black & Decker and Ernst & Young. 

Scott holds a bachelor’s degree in business administration from the University of Notre Dame, Notre Dame, Indiana, and is a certified public accountant (CPA).